StockNews.com Downgrades Omnicell (NASDAQ:OMCL) to Hold

Omnicell (NASDAQ:OMCL) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a report issued on Tuesday.

Separately, Benchmark reiterated a “buy” rating and set a $38.00 target price on shares of Omnicell in a report on Monday. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $42.20.

Omnicell Stock Performance

Shares of OMCL opened at $28.66 on Tuesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.38 and a quick ratio of 2.13. Omnicell has a one year low of $25.12 and a one year high of $71.11. The company has a 50-day simple moving average of $28.97 and a two-hundred day simple moving average of $29.44. The firm has a market capitalization of $1.32 billion, a PE ratio of -62.30, a price-to-earnings-growth ratio of 93.76 and a beta of 0.80.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, May 2nd. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.17. Omnicell had a negative net margin of 1.91% and a positive return on equity of 2.41%. The business had revenue of $246.15 million during the quarter, compared to analyst estimates of $235.70 million. On average, analysts anticipate that Omnicell will post 0.2 EPS for the current fiscal year.

Institutional Investors Weigh In On Omnicell

Several institutional investors and hedge funds have recently made changes to their positions in the company. Diversified Trust Co increased its position in shares of Omnicell by 3.3% during the second quarter. Diversified Trust Co now owns 15,364 shares of the company’s stock valued at $416,000 after acquiring an additional 494 shares in the last quarter. CWM LLC grew its position in Omnicell by 68.2% in the 2nd quarter. CWM LLC now owns 3,048 shares of the company’s stock worth $83,000 after purchasing an additional 1,236 shares during the period. Invenomic Capital Management LP grew its position in Omnicell by 75.1% in the 1st quarter. Invenomic Capital Management LP now owns 183,115 shares of the company’s stock worth $5,352,000 after purchasing an additional 78,512 shares during the period. Bayesian Capital Management LP bought a new stake in Omnicell in the 1st quarter worth approximately $398,000. Finally, Silvercrest Asset Management Group LLC grew its position in Omnicell by 4.6% in the 1st quarter. Silvercrest Asset Management Group LLC now owns 186,093 shares of the company’s stock worth $5,439,000 after purchasing an additional 8,262 shares during the period. Institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.